Skip to main content

Catalyst Calendar

Scope

Tue, Aug 11, 2026

1 updates
MANE
7:30 AM

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth Completion of patient enrollment for Phase 2/3 Study ‘306’, a 556 participant, registration-directed trial evaluating VDPHL01 in female

Trial Results • Phase 2Phase 2 Study 207 topline results Wed, Jul 1, 2026veradermics.com

Fri, Jul 17, 2026

1 updates
MANE
7:30 AM

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

NEW HAVEN, Conn. --(BUSINESS WIRE)--Jul. 17, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of

Presentation / Abstract • Phase 2/3Oral presentation Fri, Jul 17, 2026, 10:10 AM ETveradermics.com

Wed, Jul 15, 2026

1 updates
MANE
7:00 AM

Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0%

Trial Results • Phase 2Study 207 topline results Wed, Jul 15, 2026veradermics.com

Tue, Jul 14, 2026

1 updates
MANE
6:54 PM

Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET NEW HAVEN, Conn. --(BUSINESS WIRE)--Jul. 14, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss,

Results Call • Phase 2Results call Wed, Jul 15, 2026, 8:00 AM ETveradermics.com